• OPEN AN ACCOUNT
Indian Indices
Nifty
22,502.00 35.90
(0.16%)
Sensex
74,005.94 88.91
( 0.12%)
Bank Nifty
48,199.50 83.85
( 0.17%)
Nifty IT
33,438.75 56.90
( 0.17%)
Global Indices
Nasdaq
16,685.97 -12.35
(-0.07%)
Dow Jones
40,003.59 134.21
(0.34%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.47 0.01
(0.01%)
EUR-INR
90.76 0.22
(0.25%)
GBP-INR
105.79 0.36
(0.34%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

uno minda ltd
Alkem Labs slips after Baddi facility gets 10 observations from USFDA
Mar 28,2024
The inspection was conducted from 19 March 2024 to 27 March 2024. At the end of the inspection, the company has received Form 483 with 10 observations.

The company said that this inspection is part of the routine business operations and it shall submit to US FDA within the stipulated timeline, a detailed response to close out the said observations.

Alkem Laboratories is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals.

The pharma major's consolidated net profit rose 30.84% to Rs 594.96 crore on 9.31% increase in net sales to Rs 3323.87 crore in Q3 December 2023 over Q3 December 2022.